Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22319277 | 1.00 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1CRBNFKBP5 | |
| SCHEMBL7622223 | 1.00 | — | — | |
| SCHEMBL14603032 | 1.00 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1CRBNFKBP5 | |
| SCHEMBL7618081 | 1.00 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1CRBNFKBP5 | |
| SCHEMBL29018325 | 1.00 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1CRBNFKBP5 | |
| SCHEMBL22319290 | 1.00 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1CRBNFKBP5 | |
| SCHEMBL22319259 | 1.00 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1CRBNFKBP5 | |
| SCHEMBL467185 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL22469519 | 0.95 | — | — | |
| SCHEMBL14790892 | 0.92 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1CRBNFKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368001-A1 | SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2024-11-07 | — | — | US | disclosed |
| US-11987506-B2 | Salt recovery solution and processes of use thereof | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2024-05-21 | — | — | US | disclosed |
| CN-117222646-A | KRAS G12C inhibitors and uses thereof | 苏州赞荣医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11826704-B2 | Thermo-responsive solution, and method of use therefor | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2023-11-28 | — | — | US | disclosed |
| US-20230257284-A1 | SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2023-08-17 | — | — | US | disclosed |
| CN-111225875-B | Salt recovery solution and method of using salt recovery solution | 阿克福特斯技术有限公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20230043356-A1 | A SOLVENT DRYING COMPOSITION AND PROCESSES THEREFOR | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2023-02-09 | — | — | US | disclosed |
| CN-110099869-B | Thermally responsive solution and method of use thereof | 阿克福特斯技术有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220193608-A1 | THERMO-RESPONSIVE SOLUTION, AND METHOD OF USE THEREFOR | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2022-06-23 | — | — | US | disclosed |
| US-20220185754-A1 | AN ALCOHOL RECOVERY SOLUTION, AND METHOD OF USE THEREFOR | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2022-06-16 | — | — | US | disclosed |
| EP-3946712-A1 | A SOLVENT DRYING COMPOSITION AND PROCESSES THERFOR | Aquafortus Technologies Limited (NZ) | 2022-02-09 | — | — | EP | disclosed |
| CN-113966322-A | Alcohol recovery solution and use method thereof | 艾克福特士技术有限公司 | 2022-01-21 | — | — | CN | disclosed |
| EP-3935035-A1 | AN ALCOHOL RECOVERY SOLUTION, AND METHOD OF USE THEREFOR | Aquafortus Technologies Limited (NZ) | 2022-01-12 | — | — | EP | disclosed |
| CN-113891760-A | Solvent drying compositions and related methods | 阿克福特斯技术有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-11020706-B2 | Thermo-responsive solution, and method of use therefor | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2021-06-01 | — | — | US | disclosed |
| WO-2020204733-A1 | A SOLVENT DRYING COMPOSITION AND PROCESSES THERFOR | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2020-10-08 | — | — | WO | disclosed |
| US-20200308023-A1 | SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2020-10-01 | — | — | US | disclosed |
| WO-2020185096-A1 | AN ALCOHOL RECOVERY SOLUTION, AND METHOD OF USE THEREFOR | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2020-09-17 | — | — | WO | disclosed |
| EP-3691996-A2 | A SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF | Aquafortus Technologies Limited (NZ) | 2020-08-12 | — | — | EP | disclosed |
| CN-111225875-A | Salt recovery solution and method of using salt recovery solution | 阿克福特斯技术有限公司 | 2020-06-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020706-B2 | Thermo-responsive solution, and method of use therefor | AQP1, SLC39A11, THEM6 | TRIM24 3422/4885TRIM33 4450/4885ALDH1A1 1602/4885 |
| US-20230043356-A1 | A SOLVENT DRYING COMPOSITION AND PROCESSES THEREFOR | AQP1, AQP4, NOTUM | TRIM24 4597/4885TRIM33 4652/4885ALDH1A1 3984/4885 |
| US-20220185754-A1 | AN ALCOHOL RECOVERY SOLUTION, AND METHOD OF USE THEREFOR | ADH1C, ADH1A, ADH5 | TRIM24 2377/4885TRIM33 3982/4885ALDH1A1 12/4885 |
| US-20220193608-A1 | THERMO-RESPONSIVE SOLUTION, AND METHOD OF USE THEREFOR | AQP1, SLC39A11, THEM6 | TRIM24 3422/4885TRIM33 4450/4885ALDH1A1 1602/4885 |
| US-11826704-B2 | Thermo-responsive solution, and method of use therefor | AQP1, SLC39A11, THEM6 | TRIM24 3422/4885TRIM33 4450/4885ALDH1A1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.